ReviewApplied biochemistry and biotechnology2018
A Novel Approach in Treatment of Tuberculosis by Targeting Drugs to Infected Macrophages Using Biodegradable Nanoparticles.
Review in Applied biochemistry and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 23 citations in OpenAlex.
- Structural and functional characterization of mycobacterial PhoH2 and identification of potential inhibitor of its enzymatic activity.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Recent Discoveries in Nanoparticle-Macrophage Interactions: In Vitro Models for Nanosafety Testing and Novel Nanomedical Approaches for Immunotherapy.Nanomaterials (Basel, Switzerland) · 2021Article
- Beyond "Big Eaters": The Versatile Role of Alveolar Macrophages in Health and Disease.International journal of molecular sciences · 2021Review
- Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis.Frontiers in pharmacology · 2021Review
- Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.Drug delivery and translational research · 2020Review
- Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice.International journal of nanomedicine · 2020Article
- What lies beneath the airway mucosal barrier? Throwing the spotlight on antigen-presenting cell function in the lower respiratory tract.Clinical & translational immunology · 2020Review
- Enhanced Delivery of 4-Thioureidoiminomethylpyridinium Perchlorate in Tuberculosis Models with IgG Functionalized Poly(Lactic Acid)-Based Particles.Pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis, the causative agent of tuberculosis is now causing death of more than 10 million people. Because of the development of drug-resistant TB, drug delivery to the infected site through nanoparticle had been studied for long time. Nanoparticles indicate different sorts of association with the natural particles of the body. Nanoparticles can be used as controlled or specific drug delivery system. It can be through temporal controlled or can be distribution controlled. Glucose polymer-based nanoparticles might play an important role as drug delivery system in case of targeted drug delivery in the infected site of the body or in infected macrophages, as they are biodegradable so there should not be any side effects of these particles in the body and also they show very slow immune response. CD4, Beta 1, TGFb-1, IL-2, IL-13 SEC14L1, GUSB, BPI, and CCR7 are major biomarkers secreted after infection of this bacterium by the macrophages which can be used for targeted drug delivery in infected macrophages. As these markers can be used for delivery of drugs at destined position, they can be very beneficial in reducing toxicities of antituberculer drugs to the other uninfected sites and in operating only the infected macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.